Skip to content
lifestyle.duovoltart.com
Animals
Auto
Beauty & Style
Business News
Entertainment
Food
Health
Home & Family
Podcasts
Tech
Travel
Author:
AbbVie Inc.
ALLERGAN AESTHETICS HIGHLIGHTS MEDICAL WEIGHT LOSS (MWL) DATA AND THE CHANGING PROFILE OF PATIENTS
March 4, 2026
AbbVie to Present at the Leerink Partners Global Healthcare Conference
March 3, 2026
AbbVie Announces Positive Topline Results from Phase 3 AFFIRM Study Evaluating SKYRIZI® (Risankizumab) Subcutaneous Induction in Patients with Crohn’s Disease
March 2, 2026
AbbVie to Present at the TD Cowen 46th Annual Health Care Conference
February 24, 2026
AbbVie to Invest $380 Million in North Chicago to Further Expand Active Pharmaceutical Ingredient Manufacturing in the United States
February 23, 2026
U.S. Food and Drug Administration (FDA) Approves Combination Treatment of VENCLEXTA® (venetoclax) and Acalabrutinib for Previously Untreated Patients With Chronic Lymphocytic Leukemia (CLL)
February 20, 2026
AbbVie Launches Love in Mind™ to Spotlight the Emotional Impact of Migraine on Romantic Relationships
January 29, 2026
AbbVie Announces Topline Results for Epcoritamab (DuoBody® CD3xCD20) from Phase 3 EPCORE® DLBCL-1 Trial in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
January 20, 2026
←
Previous Page
1
2
3
4